Esaprazole in the treatment of gastric ulcer: preliminary clinical trial.
The activity and tolerability of esaprazole administered once a day at doses of 900 and 1350 mg/day in the treatment of gastric ulcer were evaluated in a preliminary study carried out in 47 patients. The results failed to show any difference between the two doses in terms of percentage of ulcer healing after 4 weeks (43% and 45% respectively) or 8 weeks (86% and 82%), or in the course of symptoms and signs, which improved rapidly. The safety of esaprazole was good, no modifications of laboratory parameters being observed. Although the study involved only a small number of patients, the findings obtained indicate the potential usefulness of esaprazole in the treatment of gastric ulcer.
Dal Monte
P R
PR
Department of Gastroenterology, Bellaria Hospital, Bologna, Italy.
Gullini
S
S
Saggioro
A
A
Beinat
L
L
Castiglioni
C L
CL
D002986:Clinical Trials as Topic; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use*; D013276:Stomach Ulcer / Q000188:drug therapy*
D010879:Piperazines; C042123:esaprazole